SI1625166T1 - Protitelesa masp-2 - Google Patents
Protitelesa masp-2Info
- Publication number
- SI1625166T1 SI1625166T1 SI200432248T SI200432248T SI1625166T1 SI 1625166 T1 SI1625166 T1 SI 1625166T1 SI 200432248 T SI200432248 T SI 200432248T SI 200432248 T SI200432248 T SI 200432248T SI 1625166 T1 SI1625166 T1 SI 1625166T1
- Authority
- SI
- Slovenia
- Prior art keywords
- masp
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300716 | 2003-05-12 | ||
| EP04732276.3A EP1625166B1 (en) | 2003-05-12 | 2004-05-12 | Antibodies to masp-2 |
| PCT/DK2004/000338 WO2004106384A1 (en) | 2003-05-12 | 2004-05-12 | Antibodies to masp-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1625166T1 true SI1625166T1 (sl) | 2015-08-31 |
Family
ID=33483731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200432248T SI1625166T1 (sl) | 2003-05-12 | 2004-05-12 | Protitelesa masp-2 |
| SI200432396T SI2374819T1 (sl) | 2003-05-12 | 2004-05-12 | Protitelesa proteina MASP-2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200432396T SI2374819T1 (sl) | 2003-05-12 | 2004-05-12 | Protitelesa proteina MASP-2 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9096676B2 (sl) |
| EP (2) | EP2374819B1 (sl) |
| CN (1) | CN1798769A (sl) |
| CY (2) | CY1116506T1 (sl) |
| DK (2) | DK2374819T3 (sl) |
| ES (2) | ES2629344T3 (sl) |
| HU (2) | HUE034760T2 (sl) |
| PL (2) | PL1625166T3 (sl) |
| PT (2) | PT1625166E (sl) |
| SI (2) | SI1625166T1 (sl) |
| WO (1) | WO2004106384A1 (sl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US9096676B2 (en) | 2003-05-12 | 2015-08-04 | Helion Biotech Aps | Antibodies to MASP-2 |
| WO2005123776A1 (en) * | 2004-06-10 | 2005-12-29 | Omeros Corporation | Methods for treating conditions associated with lectin-dependent complement activation |
| DK1753456T3 (en) * | 2004-06-10 | 2016-11-28 | Omeros Corp | METHODS OF TREATING CONDITIONS CONNECTED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| US8652477B2 (en) * | 2009-10-16 | 2014-02-18 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
| AU2011265532B2 (en) * | 2004-06-10 | 2014-04-24 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2013201558B2 (en) * | 2004-06-10 | 2016-03-31 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| WO2007079755A1 (en) | 2006-01-12 | 2007-07-19 | Janus Beierholm Holding Aps | Reimmunization and antibody design |
| WO2007095154A2 (en) * | 2006-02-10 | 2007-08-23 | The Brigham And Women's Hospital, Inc. | Lectin complement pathway assays and related compositions and methods |
| PL2027158T3 (pl) | 2006-05-02 | 2013-02-28 | Carviar Aps | Sposób immunizacji gatunków ptaków |
| CA2723219A1 (en) * | 2008-05-09 | 2009-11-12 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
| NZ617298A (en) | 2011-04-08 | 2015-08-28 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2013201779B2 (en) * | 2011-05-04 | 2016-01-07 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement activation |
| RS60541B1 (sr) * | 2011-05-04 | 2020-08-31 | Omeros Corp | Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| CA2906096C (en) * | 2013-03-15 | 2022-03-15 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| CN103614341B (zh) * | 2013-09-02 | 2016-07-13 | 杨旸 | 抗甘露糖结合凝聚素的单克隆抗体及试剂盒 |
| EP3750919A1 (en) * | 2013-10-17 | 2020-12-16 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US10359743B2 (en) * | 2014-11-25 | 2019-07-23 | Applied Materials, Inc. | Substrate processing systems, apparatus, and methods with substrate carrier and purge chamber environmental controls |
| CA3185172A1 (en) | 2016-01-05 | 2017-07-13 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| KR20180128941A (ko) | 2016-03-31 | 2018-12-04 | 오메로스 코포레이션 | 혈관 형성의 억제를 필요로 하는 대상체에서 혈관 형성을 억제하는 방법 |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| EP3526248A4 (en) | 2016-10-17 | 2020-07-08 | Musc Foundation for Research Development | COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE |
| TWI818919B (zh) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
| JP2021527698A (ja) * | 2018-06-22 | 2021-10-14 | オメロス コーポレーション | 様々な血栓性の疾患および障害の治療のためのｍａｓｐ−２を阻害する組成物および方法 |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| MX2021013616A (es) | 2019-05-07 | 2021-12-10 | Bayer Ag | Compuestos inhibidores de la masp y usos de estos. |
| EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| US20240010684A1 (en) | 2020-11-04 | 2024-01-11 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| CN115215937B (zh) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
| CA3225629A1 (en) * | 2021-06-30 | 2023-01-05 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-masp-2 antibodies |
| CN116615544A (zh) * | 2021-12-10 | 2023-08-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
| EP4493597A1 (en) * | 2022-03-18 | 2025-01-22 | Inmagene Pte. Ltd. | Masp-2-targetting antibodies and uses thereof |
| US12216123B2 (en) | 2023-04-25 | 2025-02-04 | Nuvance Health | Extracellular vesicle derived MASP-2 directed cancer treatment methods |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US558767A (en) | 1896-04-21 | Oyster-dredger | ||
| US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) * | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) * | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) * | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPH0662679B2 (ja) * | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) * | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5270199A (en) | 1987-08-20 | 1993-12-14 | The Children's Medical Center Corporation | Human mannose-binding protein |
| DE3852539T3 (de) | 1987-12-15 | 2005-08-04 | Gene Shears Pty. Ltd. | Ribozyme. |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) * | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) * | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) * | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4467396A (en) * | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US6492332B1 (en) * | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
| US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) * | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) * | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6008017A (en) * | 1997-01-02 | 1999-12-28 | Smithkline Beecham Corporation | Human cardiac/brain tolloid-like protein |
| US6969601B2 (en) * | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US5955309A (en) | 1997-06-18 | 1999-09-21 | Smithkline Beecham Corporation | Polynucleotide encoding G-protein coupled receptor (H7TBA62) |
| US6297024B1 (en) * | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| US7273925B1 (en) * | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| WO2000035483A1 (en) | 1998-12-15 | 2000-06-22 | The Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US6235494B1 (en) * | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| WO2000058362A1 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
| CN1359420A (zh) * | 1999-05-14 | 2002-07-17 | 斯蒂芬·蒂尔 | 重组人甘露聚糖结合型凝集素 |
| KR20080099355A (ko) | 1999-07-21 | 2008-11-12 | 오메로스 코포레이션 | 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법 |
| CA2381396A1 (en) | 1999-08-11 | 2001-02-15 | Curagen Corporation | Polynucleotides and polypeptides encoded thereby |
| AU781805B2 (en) | 1999-08-13 | 2005-06-16 | Brigham And Women's Hospital | Inhibitors of the lectin complement pathway (LCP) and their use |
| EP1238066A2 (en) | 1999-12-02 | 2002-09-11 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) * | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| WO2001084149A2 (en) * | 2000-04-29 | 2001-11-08 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| SG98393A1 (en) * | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7112414B2 (en) * | 2000-07-13 | 2006-09-26 | Jens Christian Jensenius | Masp-2, a complement-fixing enzyme, and uses for it |
| US20020094332A1 (en) * | 2001-01-18 | 2002-07-18 | Alexion Pharmaceuticals | Method of prophylaxis against large myocardial infractions |
| EP1416962A4 (en) * | 2001-07-26 | 2006-05-24 | Alexion Pharma Inc | METHOD FOR IMPROVING THE COGNITIVE FUNCTION |
| WO2003061765A1 (en) | 2002-01-22 | 2003-07-31 | Alexion Pharmaceuticals, Inc. | Method of prophylaxis against large myocardial infarctions |
| CA2474645C (en) | 2002-02-01 | 2011-08-09 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| EP1531757B1 (en) | 2002-07-19 | 2016-09-07 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| EP1545611B1 (en) | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| EP1570075A2 (en) * | 2002-12-03 | 2005-09-07 | Aarhus Universitet | Method for determing predisposition to manifestation of immune system related diseases |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| JP2006518749A (ja) | 2003-02-21 | 2006-08-17 | タノックス インコーポレーテッド | 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法 |
| US9096676B2 (en) * | 2003-05-12 | 2015-08-04 | Helion Biotech Aps | Antibodies to MASP-2 |
| WO2005014849A2 (en) * | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| EP1670910A1 (en) | 2003-09-05 | 2006-06-21 | Natimmune A/S | Masp-2 crystal structure and uses thereof |
| AU2005250499B2 (en) * | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| DK1753456T3 (en) | 2004-06-10 | 2016-11-28 | Omeros Corp | METHODS OF TREATING CONDITIONS CONNECTED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| WO2005123776A1 (en) | 2004-06-10 | 2005-12-29 | Omeros Corporation | Methods for treating conditions associated with lectin-dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| ES2902063T3 (es) * | 2006-09-08 | 2022-03-24 | Abbvie Bahamas Ltd | Proteínas de unión a interleucina-13 |
-
2004
- 2004-05-12 US US10/556,509 patent/US9096676B2/en active Active
- 2004-05-12 SI SI200432248T patent/SI1625166T1/sl unknown
- 2004-05-12 PT PT47322763T patent/PT1625166E/pt unknown
- 2004-05-12 WO PCT/DK2004/000338 patent/WO2004106384A1/en active Application Filing
- 2004-05-12 PT PT111720405T patent/PT2374819T/pt unknown
- 2004-05-12 SI SI200432396T patent/SI2374819T1/sl unknown
- 2004-05-12 EP EP11172040.5A patent/EP2374819B1/en not_active Expired - Lifetime
- 2004-05-12 DK DK11172040.5T patent/DK2374819T3/en active
- 2004-05-12 HU HUE11172040A patent/HUE034760T2/en unknown
- 2004-05-12 DK DK04732276.3T patent/DK1625166T3/en active
- 2004-05-12 PL PL04732276T patent/PL1625166T3/pl unknown
- 2004-05-12 HU HUE04732276A patent/HUE024996T2/en unknown
- 2004-05-12 ES ES11172040.5T patent/ES2629344T3/es not_active Expired - Lifetime
- 2004-05-12 CN CNA2004800155204A patent/CN1798769A/zh active Pending
- 2004-05-12 EP EP04732276.3A patent/EP1625166B1/en not_active Expired - Lifetime
- 2004-05-12 PL PL11172040T patent/PL2374819T3/pl unknown
- 2004-05-12 ES ES04732276.3T patent/ES2541134T3/es not_active Expired - Lifetime
-
2015
- 2015-06-19 US US14/745,247 patent/US10189909B2/en not_active Expired - Lifetime
- 2015-07-02 CY CY20151100572T patent/CY1116506T1/el unknown
-
2017
- 2017-06-22 CY CY20171100658T patent/CY1119106T1/el unknown
-
2018
- 2018-12-04 US US16/209,255 patent/US11008404B2/en not_active Expired - Lifetime
-
2020
- 2020-01-07 US US16/736,626 patent/US11008405B2/en not_active Expired - Lifetime
- 2020-02-20 US US16/796,179 patent/US20200199252A1/en not_active Abandoned
-
2021
- 2021-02-22 US US17/181,983 patent/US11225526B2/en not_active Expired - Lifetime
- 2021-03-16 US US17/203,396 patent/US20210221913A1/en not_active Abandoned
-
2022
- 2022-06-28 US US17/851,944 patent/US20230058435A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11225526B2 (en) | 2022-01-18 |
| US20230058435A1 (en) | 2023-02-23 |
| US11008405B2 (en) | 2021-05-18 |
| ES2541134T3 (es) | 2015-07-16 |
| PL2374819T3 (pl) | 2017-09-29 |
| PL1625166T3 (pl) | 2015-08-31 |
| US20200199252A1 (en) | 2020-06-25 |
| PT1625166E (pt) | 2015-08-20 |
| US11008404B2 (en) | 2021-05-18 |
| US20190144564A1 (en) | 2019-05-16 |
| EP2374819B1 (en) | 2017-03-22 |
| ES2629344T3 (es) | 2017-08-08 |
| US20210221913A1 (en) | 2021-07-22 |
| DK2374819T3 (en) | 2017-06-06 |
| EP1625166A1 (en) | 2006-02-15 |
| US20160096897A1 (en) | 2016-04-07 |
| US20200216566A1 (en) | 2020-07-09 |
| EP2374819A1 (en) | 2011-10-12 |
| SI2374819T1 (sl) | 2017-09-29 |
| EP1625166B1 (en) | 2015-04-08 |
| US20070009528A1 (en) | 2007-01-11 |
| CY1116506T1 (el) | 2017-03-15 |
| CY1119106T1 (el) | 2018-02-14 |
| HUE024996T2 (en) | 2016-01-28 |
| WO2004106384A1 (en) | 2004-12-09 |
| US20210261688A1 (en) | 2021-08-26 |
| CN1798769A (zh) | 2006-07-05 |
| DK1625166T3 (en) | 2015-07-13 |
| US10189909B2 (en) | 2019-01-29 |
| US9096676B2 (en) | 2015-08-04 |
| PT2374819T (pt) | 2017-07-04 |
| HUE034760T2 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1625166E (pt) | Anticorpos para masp-2 | |
| EP1616881A4 (en) | ANTI-MPL ANTIBODIES | |
| IL175608A0 (en) | Antibodies | |
| PT1599504E (pt) | Anticorpo modificado | |
| IL202681A0 (en) | Interleukin-10 antibodies | |
| EP1648512A4 (en) | ANTI-CD19 ANTIBODIES | |
| IL173557A0 (en) | Variable antibodies | |
| IL175773A0 (en) | Anti-igfr1 antibody therapeutic combinations | |
| GB0305702D0 (en) | Bispecific antibodies | |
| IL181575A0 (en) | Anti-ox40l antibodies | |
| GB0420044D0 (en) | Antibodies to m-csf | |
| IL228032A0 (en) | Antibodies | |
| SI1587542T1 (sl) | Uporaba anti-cd100 protiteles | |
| GB0420466D0 (en) | Anti-glucan antibodies | |
| AU2003218456A8 (en) | Antibodies that specifically bind to gmad | |
| EP1598368A4 (en) | ANTI-PCI neutralizing ANTIBODY | |
| ZA200701952B (en) | Anti-OX40L antibodies | |
| GB0306618D0 (en) | Antibody | |
| IL172511A0 (en) | Specific human antibodies | |
| GB0317974D0 (en) | Novel antibodies | |
| GB0329711D0 (en) | Antibodies | |
| HK1209139A1 (en) | Modified antibody | |
| GB0413479D0 (en) | Novel antibodies | |
| GB0319345D0 (en) | Variable antibodies | |
| GB0319118D0 (en) | Variable antibodies |